MetaCap

City Therapeutics (CTY) vs Nektar Therapeutics (NKTR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nektar Therapeutics is the larger company by market cap ($1.03 billion vs $1.03 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTY-13.75%NKTR-15.60%
+11%-9%-29%
Oct 16, 20261 yearNov 20, 2026
CTY-13.75%NKTR-15.60%
+10%-5%-21%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTY versus NKTR key metrics
MetricCTYNKTR
Share price$19.32$30.20
Market cap$1.03B$1.03B
1-day change+5.29%-7.19%
YTD return—-28.57%
1-year return—-44.36%
5-year return—-82.04%
EPS (TTM)$-2.53$-22.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$55.23M
Revenue growth (YoY)—-43.89%
Net income (latest FY)—$-164.08M
Gross margin—100.00%
Operating margin—-253.66%
Net margin—-297.07%
52-week high$23.88$109.00
52-week low$15.81$30.13
Distance from 52-week high-19.10%-72.29%
Analyst consensusstrong_buybuy
Avg. price target upside+93.22%+336.82%
Average volume328.87K1.12M
Shares outstanding53.39M34.21M
Employees7563
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About City Therapeutics

CTY stock →

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Nektar Therapeutics

NKTR stock →

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

CTY vs NKTR FAQ

Which is bigger, City Therapeutics or Nektar Therapeutics?

Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.03B compared with $1.03B for City Therapeutics (CTY).

Are City Therapeutics and Nektar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons